Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Shanghai Rendu Biotechnology Co (688193.SS) as of Oct 28, 2026 is 10.60 %. In the previous year, Year-over-Year Free Cash Flow Growth was 533.52 % — a change of -98.01% (lower).

FCF Growth

10.60 %

YoY

-98.01%

Last updated:

Year-over-Year Free Cash Flow Growth of Shanghai Rendu Biotechnology Co is 2025 10.60 % . Year-over-Year Free Cash Flow Growth of Shanghai Rendu Biotechnology Co was 2024 533.52 % . It decreases by -98.01% lower compared to the previous year.

The Shanghai Rendu Biotechnology Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-334.31 CNY
Jan 1, 2020
287.22 CNY
Jan 1, 2021
-63.71 CNY
Jan 1, 2022
-190.49 CNY
Jan 1, 2023
87.36 CNY
Jan 1, 2024
533.52 CNY
Jan 1, 2025
10.60 CNY
The Shanghai Rendu Biotechnology Co FCF Growth history
YEARFCF GrowthYoY
10.60 %-98.01%
533.52 %+510.69%
87.36 %-145.86%
-190.49 %+199.00%
-63.71 %-122.18%
287.22 %-185.91%
-334.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Year-over-Year Free Cash Flow Growth of Shanghai Rendu Biotechnology Co is 10.60 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Shanghai Rendu Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co